Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392546 | 0.84 | — | — | |
| SCHEMBL10224447 | 0.81 | — | — | |
| SCHEMBL395591 | 0.80 | TSHR (0.36) | — | |
| SCHEMBL390305 | 0.79 | SLC15A1 (0.43) | MMP9MEN1KMT2A | |
| SCHEMBL392739 | 0.79 | PRKCA (0.32) | — | |
| SCHEMBL389129 | 0.77 | PAM (0.42) | MEN1KMT2A | |
| SCHEMBL393552 | 0.75 | HMGCR (0.31) | — | |
| SCHEMBL394926 | 0.75 | PAM (0.51) | MEN1KMT2A | |
| SCHEMBL392561 | 0.74 | RECQL (0.33) | — | |
| SCHEMBL392732 | 0.74 | L3MBTL1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | claimed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | Q6ZSR9, GMPS, RPS10 | MMP1 4459/4885MMP2 2896/4885MMP3 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.